Holen Sie sich die Stockscreener-App
38.63
0.69%
-0.27
Handel nachbörslich:
38.63
Schlusskurs vom Vortag:
$38.90
Offen:
$38.93
24-Stunden-Volumen:
839.39K
Relative Volume:
2.40
Marktkapitalisierung:
$2.95B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-15.51
EPS:
-2.49
Netto-Cashflow:
$-156.53M
1W Leistung:
-3.55%
1M Leistung:
-1.80%
6M Leistung:
+4.15%
1J Leistung:
-5.78%
1-Tages-Spanne:
$38.00
$39.46
1-Wochen-Bereich:
$37.52
$41.62
52-Wochen-Spanne:
$35.53
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
38.63 | 2.95B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Franklin Resources Inc. - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 Shares - MarketBeat
Xenon Pharmaceuticals CFO sells shares worth $770,911 - Investing.com
Xenon Pharmaceuticals CFO sells shares worth $770,911 By Investing.com - Investing.com UK
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1%Here's Why - MarketBeat
BNP Paribas Financial Markets Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals participates in a conference call with William Blair - Nasdaq
(XENE) Trading Advice - Stock Traders Daily
Citigroup Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - MSN
Lord Abbett & CO. LLC Trims Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook - Investing.com India
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook By Investing.com - Investing.com Australia
Xenon Pharmaceuticals’ (XENE) Buy Rating Reiterated at HC Wainwright - Defense World
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? - MSN
XENE Makes Notable Cross Below Critical Moving Average - Nasdaq
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Buy Rating from HC Wainwright - MarketBeat
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - MarketBeat
Wellington Management Group LLP Buys 15,226 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Two Sigma Advisers LP Buys 64,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
(XENE) Technical Data - Stock Traders Daily
Point72 Asset Management L.P. Sells 98,732 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon's Azetukalner Shows Breakthrough Seizure Freedom Data: 33% of Patients Seizure-Free in Long-Term Study - StockTitan
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - The Manila Times
Xenon Pharmaceuticals named a Best Idea for 2025 at TD Cowen - MSN
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Janus Henderson Group PLC - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Erste Asset Management GmbH Acquires New Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
104,960 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Walleye Capital LLC - MarketBeat
Fmr LLC Has $272.35 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is Braidwell LP's 7th Largest Position - MarketBeat
Vestal Point Capital LP Has $32.48 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Natixis Advisors LLC Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Loomis Sayles & Co. L P - MarketBeat
Xenon Pharmaceuticals Inc. to Showcase New Long-Term Azetukalner Data at AES 2024 - Marketscreener.com
Xenon Pharmaceuticals' SWOT analysis: stock poised for breakthrough in epilepsy - Investing.com
Xenon Pharmaceuticals Unveils New Data at AES 2024 - TipRanks
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 - The Manila Times
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Westfield Capital Management Co. LP - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 17,953 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Sells $200,922.28 in Stock - MarketBeat
Xenon Pharmaceuticals director sells $200,946 in stock - Investing.com India
Xenon Pharmaceuticals director sells $200,946 in stock By Investing.com - Investing.com Australia
First Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Eye Opportunities With Xenon Pharmaceuticals - Evrim Ağacı
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap DownHere's What Happened - MarketBeat
What is HC Wainwright's Estimate for XENE FY2024 Earnings? - MarketBeat
FY2024 EPS Estimates for XENE Reduced by Cantor Fitzgerald - MarketBeat
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AULIN SHERRY | Chief Financial Officer |
Dec 18 '24 |
Sale |
41.21 |
18,709 |
770,912 |
0 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):